This settlement is closed!
Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!
Update:
- Final approval for this class action settlement was granted Dec. 4, 2023.
- Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.
Indivior agreed to a $30 million antitrust class action lawsuit settlement to resolve claims that it worked with other companies to raise the cost of Suboxone, a treatment for opioid addiction.
The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011 and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia.
The antitrust class action lawsuit accused Indivior of conspiring with other companies to raise the price of Suboxone and its generic alternatives. According to the plaintiffs in the case, they were forced to overpay for Suboxone as a result of the antitrust scheme.
Individor is a pharmaceutical company that specializes in addiction and mental health treatment.
Indivior hasn’t admitted any wrongdoing but agreed to a $30 million settlement to resolve the antitrust class action lawsuit.
Under the terms of the Suboxone class action settlement, class members can receive a proportional share of the net settlement fund based on the amount they spent in qualifying purchases. Exact payments will vary depending on the number of claims filed and other factors.
The deadline for exclusion is Oct. 12, 2023. The objection deadline is Oct. 5, 2023.
The final approval hearing for the Suboxone antitrust class action lawsuit settlement is scheduled for Oct. 19, 2023.
In order to receive a settlement payment, class members must submit a valid claim form by Feb. 17, 2024.
Who’s Eligible
Individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011, and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia
Potential Award
Varies
Proof of Purchase
Records from the class member’s pharmacy showing they purchased Suboxone and its AB‐rated generic equivalents at least once or a note or records from their doctor describing the amount of Suboxone and its AB‐rated generic equivalents prescribed.
Class members may have a claim even if they are not able to provide any of the above claim documentation as long as they provide the certification on the claim form. However, the settlement administrator may ask those who do not provide the above documentation for additional claim documentation after the class member submits their claim form.
Claim Form
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
02/17/2024
Case Name
In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, Case No. 2:13-md-02445-MSG, in the U.S. District Court for the Eastern District of Pennsylvania
Final Hearing
10/19/2023
Settlement Website
Claims Administrator
Suboxone End-Payor Antitrust Litigation
c/o A.B. Data, Ltd.
P.O. Box 173080
Milwaukee, WI 53217
[email protected]
877-311-3735
Class Counsel
Kenneth A Wexler
WEXLER BOLEY & ELGERSMA LLP
Steve Shadowen
HILLIARD SHADOWEN LLP
Michael M. Buchman
MOTLEY RICE LLC
Marvin A Miller
MILLER LAW LLC
Jeffrey L Kodroff
SPECTOR ROSEMAN & KODROFF PC
Defense Counsel
Justin Bernick
HOGAN LOVELLS US LLP
Read About More Class Action Lawsuits & Class Action Settlements:
- CVS lidocaine false advertising $3.8M class action settlement
- Allwell Behavioral Health data breach $650K class action settlement
- Right Guard antiperspirant $1.95M class action settlement
- Instagram BIPA $68.5M class action settlement
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2025 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Cellphone wrong-number robocalls could be worth $500-$1,500 per violation of the federal TCPA
December 12, 2025 | TCPA Class Action Lawsuits
295 thoughts onSuboxone indirect purchasers antitrust $30M class action settlement
Per the 12/10/25 posted documents, the Motion for Authorization to Distribute the Settlement Funds was approved making it “likely” that the payments will be distributed by the end of Feb, 2026 and maybe even sooner. It is important to note that the distribution plan changed from being a fractional payment based upon claim amount to a simple “pro rata”. This was likely done to expedite the distribution timeline. Out of the 10,300 total claims, it still has not been established what is the numeric breakdown of 10,300 between the number of Repealer and Non-Repealer claims making it impossible to firmly estimate the claim amounts. Roughly assuming a 90/10 split similar to the financial split (which is likely incorrect), that would result in approximately a $700-1000 payment per claim. If anyone has additional information on the Repealer/Non-Replealer claim numbers, please post it here. Thank you.